The powerful cytotoxic properties of α-particles emitted by [225Ac]Ac-DOTA-trastuzumab may make this agent more effective than trastuzumab for treatment of HER2-positive BC, particularly when delivered to the brain, and may overcome resistance of these tumours to HER2-targeted agents. Here, ERBB2 is linked to neoplasm.